Onyx gains on carfilzomib data

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) gained $4.54 (21%) to $26.04 on Monday after reporting data from the pivotal Phase IIb PX-171-003-A1 trial of carfilzomib to treat relapsed and refractory multi...